157 related articles for article (PubMed ID: 32369961)
21. The effects of ozone application on genotoxic damage and wound healing in bisphosphonate-applied human gingival fibroblast cells.
Akdeniz SS; Beyler E; Korkmaz Y; Yurtcu E; Ates U; Araz K; Sahin FI; Torun OY
Clin Oral Investig; 2018 Mar; 22(2):867-873. PubMed ID: 28699091
[TBL] [Abstract][Full Text] [Related]
22. Development of Medication-Related Osteonecrosis of the Jaw After Extraction of Teeth With Experimental Periapical Disease.
Hadaya D; Soundia A; Gkouveris I; Dry SM; Aghaloo TL; Tetradis S
J Oral Maxillofac Surg; 2019 Jan; 77(1):71-86. PubMed ID: 30218655
[TBL] [Abstract][Full Text] [Related]
23. Fluorescence-guided surgery for the treatment of medication-related osteonecrosis of the jaw: A prospective cohort study.
Otto S; Ristow O; Pache C; Troeltzsch M; Fliefel R; Ehrenfeld M; Pautke C
J Craniomaxillofac Surg; 2016 Aug; 44(8):1073-80. PubMed ID: 27263757
[TBL] [Abstract][Full Text] [Related]
24. Histologic analysis of medication-related osteonecrosis of the jaw compared with antiresorptive-exposed bone and other infectious, inflammatory, and necrotic jaw diseases.
Yuan A; Munz A; Reinert S; Hoefert S
Oral Surg Oral Med Oral Pathol Oral Radiol; 2020 Feb; 129(2):133-140. PubMed ID: 31606424
[TBL] [Abstract][Full Text] [Related]
25. Osteoclast profile of medication-related osteonecrosis of the jaw secondary to bisphosphonate therapy: a comparison with osteoradionecrosis and osteomyelitis.
Gross C; Weber M; Creutzburg K; Möbius P; Preidl R; Amann K; Wehrhan F
J Transl Med; 2017 Jun; 15(1):128. PubMed ID: 28587628
[TBL] [Abstract][Full Text] [Related]
26. Early bony changes associated with bisphosphonate-related osteonecrosis of the jaws in rats: A longitudinal in vivo study.
Vilarinho JLP; Ferrare N; Moreira AMR; Moura HF; Acevedo AC; Chaves SB; Melo NS; Leite AF; Macedo SB; de Souza MP; Guimarães ATB; Figueiredo PT
Arch Oral Biol; 2017 Oct; 82():79-85. PubMed ID: 28622548
[TBL] [Abstract][Full Text] [Related]
27. The effects of different doses of teriparatide on bisphosphonate-related osteonecrosis of the jaw in mice.
Yu W; Su J
Oral Dis; 2020 Apr; 26(3):609-620. PubMed ID: 31903673
[TBL] [Abstract][Full Text] [Related]
28. Platelet rich fibrin in the management of medication-related osteonecrosis of the jaw: a clinical and histopathological evaluation.
Inchingolo F; Cantore S; Dipalma G; Georgakopoulos I; Almasri M; Gheno E; Motta A; Marrelli M; Farronato D; Ballini A; Marzullo A
J Biol Regul Homeost Agents; 2017; 31(3):811-816. PubMed ID: 28958140
[TBL] [Abstract][Full Text] [Related]
29. Allogeneic Bone Marrow Mesenchymal Stem Cell Transplantation in Tooth Extractions Sites Ameliorates the Incidence of Osteonecrotic Jaw-Like Lesions in Zoledronic Acid-Treated Rats.
Rodríguez-Lozano FJ; Oñate-Sánchez R; Gonzálvez-García M; Vallés-Bergadá M; Martínez CM; Revilla-Nuin B; Guerrero-Gironés J; Moraleda JM; García-Bernal D
J Clin Med; 2020 May; 9(6):. PubMed ID: 32486396
[TBL] [Abstract][Full Text] [Related]
30. Current Controversies on the Pathogenesis of Medication-Related Osteonecrosis of the Jaw.
Wat WZM
Dent J (Basel); 2016 Oct; 4(4):. PubMed ID: 29563480
[TBL] [Abstract][Full Text] [Related]
31. PRGF exerts a cytoprotective role in zoledronic acid-treated oral cells.
Anitua E; Zalduendo M; Troya M; Orive G
Clin Oral Investig; 2016 Apr; 20(3):513-21. PubMed ID: 26201455
[TBL] [Abstract][Full Text] [Related]
32. Nd:YAG laser biostimulation in the treatment of bisphosphonate-associated osteonecrosis of the jaw: clinical experience in 28 cases.
Vescovi P; Merigo E; Manfredi M; Meleti M; Fornaini C; Bonanini M; Rocca JP; Nammour S
Photomed Laser Surg; 2008 Feb; 26(1):37-46. PubMed ID: 18248160
[TBL] [Abstract][Full Text] [Related]
33. The role of surgical resection in the management of bisphosphonate-related osteonecrosis of the jaws.
Carlson ER; Basile JD
J Oral Maxillofac Surg; 2009 May; 67(5 Suppl):85-95. PubMed ID: 19371819
[TBL] [Abstract][Full Text] [Related]
34. Medication-related osteonecrosis of the jaw: risk factors in patients under biphosphonate versus patients under antiresorptive-antiangiogenic drugs.
Ghidini G; Manfredi M; Giovannacci I; Mergoni G; Sarraj A; Mureddu M; Giunta G; Bonanini M; Meleti M; Vescovi P
Minerva Stomatol; 2017 Aug; 66(4):135-140. PubMed ID: 28497661
[TBL] [Abstract][Full Text] [Related]
35. Effects of a low-level diode laser on oral keratinocytes, oral fibroblasts, endothelial cells and osteoblasts incubated with bisphosphonates: An
Walter C; Pabst AM; Ziebart T
Biomed Rep; 2015 Jan; 3(1):14-18. PubMed ID: 25469239
[TBL] [Abstract][Full Text] [Related]
36. A novel soft-tissue in vitro model for bisphosphonate-associated osteonecrosis.
Scheper M; Chaisuparat R; Cullen K; Meiller T
Fibrogenesis Tissue Repair; 2010 Apr; 3():6. PubMed ID: 20359336
[TBL] [Abstract][Full Text] [Related]
37. Osteoclastic expression of higher-level regulators NFATc1 and BCL6 in medication-related osteonecrosis of the jaw secondary to bisphosphonate therapy: a comparison with osteoradionecrosis and osteomyelitis.
Wehrhan F; Gross C; Creutzburg K; Amann K; Ries J; Kesting M; Geppert CI; Weber M
J Transl Med; 2019 Mar; 17(1):69. PubMed ID: 30832685
[TBL] [Abstract][Full Text] [Related]
38. Microbial diversity in infections of patients with medication-related osteonecrosis of the jaw.
Zirk M; Wenzel C; Buller J; Zöller JE; Zinser M; Peters F
Clin Oral Investig; 2019 May; 23(5):2143-2151. PubMed ID: 30276516
[TBL] [Abstract][Full Text] [Related]
39. Dental extraction following zoledronate, induces osteonecrosis in rat's jaw.
Vidal-Gutiérrez X; Gómez-Clavel JF; Gaitán-Cepeda LA
Med Oral Patol Oral Cir Bucal; 2017 Mar; 22(2):e177-e184. PubMed ID: 28160593
[TBL] [Abstract][Full Text] [Related]
40. Incidence and Risk Factors of Osteonecrosis of the Jaw in Advanced Cancer Patients after Treatment with Zoledronic Acid or Denosumab: A Retrospective Cohort Study.
Kajizono M; Sada H; Sugiura Y; Soga Y; Kitamura Y; Matsuoka J; Sendo T
Biol Pharm Bull; 2015; 38(12):1850-5. PubMed ID: 26632176
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
